Sarepta Therapeutics Inc. (SRPT) Jumped After Eteplirsen Critic Leaves FDA

Dr. Ronald Farkas, a leading critic against Sarepta Therapeutics Inc.'s (SRPT) eteplirsen, has reportedly left the FDA for another employment opportunity. The drug is a potential treatment for the genetic disease Duchenne muscular dystrophy.

from RTT - Before the Bell http://ift.tt/2cpHots
via IFTTT